A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

计划入组 91 人 · 首次发布于 2024 年 8 月 1 日

Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer

计划入组 15 人 · 首次发布于 2022 年 9 月 16 日

Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors

计划入组 20 人 · 首次发布于 2022 年 9 月 16 日

SV-102

E-Sync T Cell Therapy (Glioblastoma)

T-102

T-Knife GmbH

Germany

PH & T SpA

Italy

Fakultní nemocnice u sv. Anny v Brně

Czech Republic

Syncromune's SYNC-T Therapy Shows Bone Metastases Resolution in Phase 1 Prostate Cancer Trial

Syncromune's SYNC-T Therapy Shows 87% Response Rate in Metastatic Prostate Cancer Phase 1 Trial

Syncromune to Present Phase 1 Data on Novel SYNC-T Therapy for Metastatic Prostate Cancer at ASCO 2025